Abstract 1465P
Background
Pembrolizumab monotherapy and immune checkpoint inhibitor plus chemotherapy (ICI/Chemo) have been approved as first-line treatment for non-small cell lung cancer (NSCLC) with programmed death ligand 1 tumor proportion score (PD-L1 TPS) ≥50%. However, the clear distinction between the two therapeutic options remains unclear. It was reported that using proton pump inhibitors (PPI) and antibiotics correlated with poorer treatment outcomes of ICI monotherapy for NSCLC.
Methods
We retrospectively enrolled consecutive PD-L1 TPS ≥50% advanced NSCLC patients who received pembrolizumab monotherapy or ICI/Chemo as first-line treatment. We analyzed the association between treatment outcome and patient characteristics, including concomitant drug history in each group. Comparing the treatment outcome, propensity score matching was used to reduce bias.
Results
The study included 425 patients, with 271 receiving pembrolizumab monotherapy and 154 receiving ICI/Chemo. According to the multivariate analysis, a history of PPI usage was independently associated with shorter progression-free survival (PFS) in pembrolizumab monotherapy group(hazard ratio (HR): 1.38, 95.0% CI: 1.00–1.91; P = 0.048), but not in ICI/Chemo group (HR: 0.83, 95.0% CI: 0.48–1.45; P = 0.515). In patients with a history of PPI, both the median PFS (19.3 months vs. 5.7 months, P=0.002) and the median overall survival (OS) (not reached vs. 18.4 months, P=0.025) were significantly longer in ICI/Chemo group than in pembrolizumab monotherapy group. In patients without a history of PPI, the median PFS (18.8 months vs. 10.6 months, P=0.259) and the median OS (not reached vs. 29.9 months, P=0.211) was not significantly different between each group.
Conclusions
History of PPI usage was negatively associated with treatment outcome of pembrolizumab monotherapy, but not ICI/Chemo in NSCLC patients with PD-L1 expression ≥50%. Our observations in real-world settings suggest that the history of PPI usage may be a predictive clinical factor to be considered in treatment decision-making in this population.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1368P - LUMINATE 102: A real-world study on biomarker testing rates among patients with non-small cell lung cancer (NSCLC) across lines of therapy
Presenter: Charu Aggarwal
Session: Poster session 20
1369P - BrigAlec study: Focus on alectinib efficacy after brigatinib exposure in BrigALK2 study (GFPC 02-2019)
Presenter: Renaud Descourt
Session: Poster session 20
1370P - Efficacy and safety of ensartinib in ALK-positive non-small cell lung cancer patients with brain metastases: A multicenter, open-label, single-arm, phase II study
Presenter: Jianhua Chang
Session: Poster session 20
1371P - First-line alectinib vs. brigatinib in advanced metastatic NSCLC with ALK rearrangement: Real-world data
Presenter: Young Kyung Jeon
Session: Poster session 20
1372P - Repotrectinib in patients (pts) with NTRK fusion-positive (NTRK+) advanced solid tumors, including NSCLC: Update from the phase I/II TRIDENT-1 trial
Presenter: Ben Solomon
Session: Poster session 20
1373P - Efficacy and safety of taletrectinib in patients (Pts) with ROS1+ non-small cell lung cancer (NSCLC): Interim analysis of global TRUST-II study
Presenter: Maurice Pérol
Session: Poster session 20
1374P - Survival and therapy analysis of small-scale ROS1-mutant non-small cell lung cancer (NSCLC) patients
Presenter: Moritz Glaser
Session: Poster session 20
1375P - Beamion Lung 1, an ongoing phase Ia/Ib trial of the HER2 TKI, BI 1810631 in patients (pts) with advanced solid tumors with HER2 aberrations: Latest data
Presenter: Frans Opdam
Session: Poster session 20
1377P - Differential impact of EGFR exon 20 insertion location on tyrosine kinase inhibitor sensitivity
Presenter: Xiuning Le
Session: Poster session 20
1378P - Efficacy and safety of tunlametinib (HL-085) combined with vemurafenib in patients with advanced BRAF V600-mutated solid tumors: A multicenter, phase I study
Presenter: Yuan-Kai Shi
Session: Poster session 20